Stephen G. Jones
Assistant Professor
Also affiliated: Centers for Disease Control and Prevention (2015); United States Fish and Wildlife Service (2005); Vanderbilt University (2015); Sherwood Forest Hospitals NHS Foundation Trust (2015–2024); Blue Cross and Blue Shield of Kansas City (2009–2012); Schaffner (Switzerland) (2015); Queen's Medical Centre (2002); BlueCross BlueShield of South Carolina Foundation (2009–2016); Manor Hospital (2009); Mass General Brigham (2019)
Faculty Researcher
Peds Pediatrics, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Stephen G. Jones is an Assistant Professor in the Department of Pediatrics at the University of Arkansas for Medical Sciences. His research focuses on the genomic and clinical consequences of cancer treatments, particularly in Hodgkin lymphoma. Jones has investigated the substitution of dacarbazine for procarbazine in escalated BEACOPP regimens, studying its impact on reducing post-treatment mutational burden in hematopoietic stem and progenitor cells while maintaining clinical efficacy and potentially lowering toxicity. His work has also explored the burden of genitourinary malignancies in Southeast Asia and breast cancer among adolescents and young adults in North Africa.
Jones's scholarship metrics include an h-index of 10, with 43 total publications and 469 total citations. He collaborates with researchers such as Matthew Bell and John Alberty at the University of Arkansas for Medical Sciences. His most recent publication is from 2025, indicating recent activity in his research endeavors.
Metrics
- h-index: 11
- Publications: 43
- Citations: 471
Selected Publications
-
Incidental Detection of Acute Leukemia During Genetic Evaluation of Neurodevelopmental Disorder in a Pediatric Clinic: A Case Report (2026)
-
Trofinetide-Induced Enterocolitis Syndrome in a Child with Rett Syndrome (2025)
-
Potential neonatal toxicity of new psychoactive substances (2023)
-
Prediction of milk plasma ratio for amphoteric substances (2022)
-
Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid <i>N</i>‐(adamantan‐1‐yl)‐1‐(5‐fluoropentyl)‐1<i>H</i>‐indole‐3‐carboxamide (STS‐135) (2020)
-
Comparaisons continentales des caractéristiques des patients dans PALISADE, étude de phase 3 d’AR101 dans l’allergie à l’arachide (2019)
-
Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22) (2019)
-
Sublingual Immunotherapy for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Multicenter Trial (CoFAR) (2012)
-
Release of Soluble Protein from Peanut and Its Adsorption by Activated Charcoal In Vitro and In Vivo (2009)
Collaboration Network
Top Collaborators
- Potential neonatal toxicity of new psychoactive substances
- Prediction of milk plasma ratio for amphoteric substances
- Potential neonatal toxicity of new psychoactive substances
- Prediction of milk plasma ratio for amphoteric substances
- Potential neonatal toxicity of new psychoactive substances
- Potential neonatal toxicity of new psychoactive substances
- Potential neonatal toxicity of new psychoactive substances
- Potential neonatal toxicity of new psychoactive substances
- Potential neonatal toxicity of new psychoactive substances
- Trofinetide-Induced Enterocolitis Syndrome in a Child with Rett Syndrome
- Trofinetide-Induced Enterocolitis Syndrome in a Child with Rett Syndrome
Similar Researchers
Based on overlapping research topics